Literature DB >> 24306958

The density of CD8+ T-cell infiltration and expression of BCL2 predicts outcome of primary diffuse large B-cell lymphoma of bone.

Hajnalka Rajnai1, Fenna H Heyning, Lianne Koens, Anna Sebestyén, Hajnalka Andrikovics, Pancras C W Hogendoorn, András Matolcsy, Ágota Szepesi.   

Abstract

Primary bone lymphoma (PBL) comprises 5 % of all extranodal non-Hodgkin's lymphomas (NHLs). Diffuse large B-cell lymphoma (DLBCL) accounts for the majority of cases, which is the most heterogeneous group of lymphomas. Previous studies suggested that besides the tumor cell phenotype, phosphatidylinositol 3-kinase/acutely transforming retrovirus/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway activity and the composition of the immune-microenvironment of DLBCL influence the clinical behavior of the disease. The aim of our study was to determine the relationship between clinical factors, tumor cell phenotype, microenvironment, PI3K/AKT/mTOR pathway activity, and disease outcome in primary bone diffuse large B-cell lymphoma (PB-DLBCL). We constructed tissue-microarrays from 41 cases of PB-DLBCL. To characterize tumor cell phenotype, T-cell subsets, macrophages, and PI3K/AKT/mTOR pathway activity immunohistochemical stainings were evaluated. Kaplan-Meier survival analysis provided evidence that age (≤65), CD3 and CD8+ T cell infiltrations >5 %, low BCL2 expression of the tumor cells (≤30 %), and low proliferation index (Ki67 ≤ 57 %) were associated with favorable outcome of PB-DLBCL patients. Multivariate analysis revealed that CD8+ T cell infiltration >5 % and low BCL2 expression (≤30 %) were independent predictors of survival. Increased macrophage infiltration (>10 %) showed tendency toward an adverse prognostic effect. International prognostic index, tumor cell phenotype (GCB or ABC), MYC protein expression, and activation of PI3K/AKT/mTOR pathway had no significant impact on survival. However, mTOR activity showed a significant correlation with activated B-cell phenotype. We conclude that CD8 and BCL2 expressions are potential prognostic markers for PB-DLBCL patients and the PI3K/AKT/mTOR pathway appears to be an additional therapeutic target in PB-DLBCL with activated-B-cell phenotype.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24306958     DOI: 10.1007/s00428-013-1519-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  31 in total

1.  High expression of tumor-infiltrating macrophages correlates with poor prognosis in patients with diffuse large B-cell lymphoma.

Authors:  Qi-chun Cai; Hong Liao; Su-xia Lin; Yi Xia; Xiao-xaio Wang; Yan Gao; Ze-xiao Lin; Jia-bin Lu; Hui-qiang Huang
Journal:  Med Oncol       Date:  2011-12-24       Impact factor: 3.064

2.  Cd4+ T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome.

Authors:  S M Ansell; M Stenson; T M Habermann; D F Jelinek; T E Witzig
Journal:  J Clin Oncol       Date:  2001-02-01       Impact factor: 44.544

3.  A clinicopathological retrospective study of 131 patients with primary bone lymphoma: a population-based study of successively treated cohorts from the British Columbia Cancer Agency.

Authors:  K M Ramadan; T Shenkier; L H Sehn; R D Gascoyne; J M Connors
Journal:  Ann Oncol       Date:  2006-10-03       Impact factor: 32.976

4.  Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response.

Authors:  Stefano Monti; Kerry J Savage; Jeffery L Kutok; Friedrich Feuerhake; Paul Kurtin; Martin Mihm; Bingyan Wu; Laura Pasqualucci; Donna Neuberg; Ricardo C T Aguiar; Paola Dal Cin; Christine Ladd; Geraldine S Pinkus; Gilles Salles; Nancy Lee Harris; Riccardo Dalla-Favera; Thomas M Habermann; Jon C Aster; Todd R Golub; Margaret A Shipp
Journal:  Blood       Date:  2004-11-18       Impact factor: 22.113

5.  Loss of MHC class II gene and protein expression in diffuse large B-cell lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Profiling Project.

Authors:  Lisa M Rimsza; Robin A Roberts; Thomas P Miller; Joseph M Unger; Michael LeBlanc; Rita M Braziel; Dennis D Weisenberger; Wing C Chan; H Konrad Muller-Hermelink; Elaine S Jaffe; Randy D Gascoyne; Elias Campo; Deborah A Fuchs; Catherine M Spier; Richard I Fisher; Jan Delabie; Andreas Rosenwald; Louis M Staudt; Thomas M Grogan
Journal:  Blood       Date:  2004-02-19       Impact factor: 22.113

6.  MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy.

Authors:  Alexandra Valera; Armando López-Guillermo; Teresa Cardesa-Salzmann; Fina Climent; Eva González-Barca; Santiago Mercadal; Iñigo Espinosa; Silvana Novelli; Javier Briones; José L Mate; Olga Salamero; Juan M Sancho; Leonor Arenillas; Sergi Serrano; Nadina Erill; Daniel Martínez; Paola Castillo; Jordina Rovira; Antonio Martínez; Elias Campo; Luis Colomo
Journal:  Haematologica       Date:  2013-05-28       Impact factor: 9.941

7.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.

Authors:  Christine P Hans; Dennis D Weisenburger; Timothy C Greiner; Randy D Gascoyne; Jan Delabie; German Ott; H Konrad Müller-Hermelink; Elias Campo; Rita M Braziel; Elaine S Jaffe; Zenggang Pan; Pedro Farinha; Lynette M Smith; Brunangelo Falini; Alison H Banham; Andreas Rosenwald; Louis M Staudt; Joseph M Connors; James O Armitage; Wing C Chan
Journal:  Blood       Date:  2003-09-22       Impact factor: 22.113

8.  Genes associated with the tumour microenvironment are differentially expressed in cured versus primary chemotherapy-refractory diffuse large B-cell lymphoma.

Authors:  Johan Linderoth; Patrik Edén; Mats Ehinger; Jeanette Valcich; Mats Jerkeman; Pär-Ola Bendahl; Mattias Berglund; Gunilla Enblad; Martin Erlanson; Göran Roos; Eva Cavallin-Ståhl
Journal:  Br J Haematol       Date:  2008-05       Impact factor: 6.998

9.  Correlation of high numbers of intratumoral FOXP3+ regulatory T cells with improved survival in germinal center-like diffuse large B-cell lymphoma, follicular lymphoma and classical Hodgkin's lymphoma.

Authors:  Alexandar Tzankov; Cecile Meier; Petra Hirschmann; Philip Went; Stefano A Pileri; Stephan Dirnhofer
Journal:  Haematologica       Date:  2008-01-26       Impact factor: 9.941

10.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

View more
  6 in total

1.  Stromal immune infiltration in HIV-related diffuse large B-cell lymphoma is associated with HIV disease history and patient survival.

Authors:  Chun Chao; Lanfang Xu; Michael J Silverberg; Otoniel Martínez-Maza; Lie-Hong Chen; Brandon Castor; Donald I Abrams; Hongbin D Zha; Reina Haque; Jonathan Said
Journal:  AIDS       Date:  2015-09-24       Impact factor: 4.177

2.  miR-21 inhibitor suppresses proliferation and migration of nasopharyngeal carcinoma cells through down-regulation of BCL2 expression.

Authors:  Yumei Li; Limei Yan; Wenyu Zhang; Hui Wang; Wei Chen; Nan Hu; Hesheng Ou
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

3.  CD3+/CD8+ T-cell density and tumoral PD-L1 predict survival irrespective of rituximab treatment in Chinese diffuse large B-cell lymphoma patients.

Authors:  Yunfei Shi; Lijuan Deng; Yuqin Song; Dongmei Lin; Yumei Lai; LiXin Zhou; Lei Yang; Xianghong Li
Journal:  Int J Hematol       Date:  2018-05-10       Impact factor: 2.490

4.  Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.

Authors:  Ruben A L de Groen; Ronald van Eijk; Stefan Böhringer; Tom van Wezel; Richard Raghoo; Dina Ruano; Patty M Jansen; Inge Briaire-de Bruijn; Fleur A de Groot; Karin Kleiverda; Liane Te Boome; Valeska Terpstra; Henriette Levenga; Alina Nicolae; Eduardus F M Posthuma; Isabelle Focke-Snieders; Lizan Hardi; Wietske C E den Hartog; Lara H Bohmer; Pancras C W Hogendoorn; Anke van den Berg; Arjan Diepstra; Marcel Nijland; Pieternella J Lugtenburg; Marie José Kersten; Steven T Pals; Hendrik Veelken; Judith V M G Bovée; Arjen H G Cleven; Joost S P Vermaat
Journal:  Blood Adv       Date:  2021-10-12

5.  Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma.

Authors:  Tingting Zhang; Tianyuan Ren; Zheng Song; Jing Zhao; Lei Jiao; Zhenzhen Zhang; Jin He; Xianming Liu; Lihua Qiu; Lanfang Li; Shiyong Zhou; Bin Meng; Qiongli Zhai; Xiubao Ren; Zhengzi Qian; Xianhuo Wang; Huilai Zhang
Journal:  J Immunol Res       Date:  2020-10-29       Impact factor: 4.818

6.  High proportion of anergic B cells in the bone marrow defined phenotypically by CD21(-/low)/CD38- expression predicts poor survival in diffuse large B cell lymphoma.

Authors:  Sewa Rijal; Johanna Kok; Caitlin Coombes; Lillian Smyth; Jayde Hourigan; Sanjiv Jain; Dipti Talaulikar
Journal:  BMC Cancer       Date:  2020-11-03       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.